NovaBridge Reports H1 2026 Loss of $37.9M, Cash Runway Through 2028

summarizeSummary

NovaBridge reported a $37.9M H1 2026 net loss, up from $8.7M a year ago, as R&D and administrative spending surged. The company holds $215.9M in cash and expects runway through givastomig's Phase 3 interim readout in 2028.

check_boxKey Events · Earnings and Guidance · NBP

• H1 2026 Net Loss Widens to $37.9M

  Net loss increased from $8.7M in H1 2025 to $37.9M in H1 2026, driven by higher R&D and administrative expenses.

• Cash Position of $215.9M

  Cash, cash equivalents, short-term investments, and equity investment at fair value totaled $215.9M as of June 30, 2026, providing runway through givastomig's planned Phase 3 interim readout in 2028.

• R&D Spending Surges on Givastomig

  R&D expenses rose to $14.3M from $4.1M, primarily due to the ramp-up of givastomig Phase 1b and Phase 2 clinical trials.

• Administrative Costs Include $3.8M Write-off

  Administrative expenses increased to $26.4M from $8.3M, including a $3.8M write-off of deferred offering costs related to the abandoned HKEx dual primary listing.

auto_awesomeAnalysis · NBP · Life Sciences

The first-half 2026 results reveal a sharp increase in spending as NovaBridge advances its lead oncology asset givastomig toward a Phase 3 trial. The net loss widened to $37.9 million from $8.7 million a year earlier, driven by a $10.2 million jump in R&D and an $18.1 million increase in administrative costs, including a $3.8 million write-off of deferred offering fees from the abandoned HKEx dual listing. The company ended June with $215.9 million in cash and investments, which management says funds operations through givastomig's planned Phase 3 interim readout in 2028. The filing also confirms the 2026 Share Incentive Plan approved in July, adding 11.96 million shares to the equity pool. For a clinical-stage biotech with no revenue, the key question is whether the cash runway is sufficient to reach value-creating milestones without further dilution.